Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair Enhances Oral Desensitization in Peanut Allergic Patients
NCT01290913Phase 2Completed
- Start
- Feb 2011
- Primary completion
- Sep 2013
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in peanut allergy. Started Feb 2011; status: completed.
02
Drugs
omalizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT01290913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290913.